 The first therapeutic applications of ZFNs are likely to involve "ex vivo" therapy using a patients own stem cells.After editing the stem cell genome, the cells could be expanded in culture and reinserted into the patient to produce differentiated cells with corrected functions.Initial targets likely include the causes of monogenic diseases, such as the IL2Rγ gene and the b-globin gene for gene correction and CCR5 gene for mutagenesis and disablement.